Welcome to our dedicated page for ARS Pharms SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. ARS Pharma describes itself as a commercial-stage biopharmaceutical company focused on epinephrine nasal spray products for emergency treatment of Type I allergic reactions, including anaphylaxis, and its filings help investors understand how this business is being financed, governed, and developed.
Recent Forms 8-K illustrate several important themes. Some filings report financial results and business updates for specific quarters, where ARS Pharma furnishes press releases discussing revenue from neffy, commercial launch progress, and cash resources. These items fall under “Results of Operations and Financial Condition” and “Regulation FD Disclosure,” and are incorporated by reference to attached exhibits.
Other 8-Ks describe material definitive agreements and financing arrangements, such as the senior secured term loan facility of up to $250 million with affiliates of RA Capital Management and OMERS Life Sciences. These filings outline the structure of the term loans, interest terms, collateral, covenants, and intended use of proceeds, which ARS Pharma states include funding research, development, and commercialization activities for its products, as well as general corporate purposes.
ARS Pharma also uses 8-K filings to disclose legal and intellectual property developments. For example, the company has reported receiving a Paragraph IV certification notice related to a proposed generic version of neffy 2 mg (epinephrine nasal spray) and has stated its intention to pursue patent infringement litigation to defend its listed U.S. patents.
Through Stock Titan, users can track these filings as they are posted to EDGAR and use AI-powered summaries to quickly understand the main points of each document. This includes highlighting where ARS Pharma discusses neffy’s commercialization, financing arrangements, intellectual property strategy, and other material events that may be relevant to shareholders and prospective investors.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider transaction
Director Rajeev Dadoo reported the receipt of 30,000 non-qualified stock options on 25 June 2025. The options carry an exercise price of $17.26 per share and expire on 24 June 2035, giving a 10-year contractual life. According to the filing, the award vests 100 % on the earlier of 25 June 2026 or the date of the company’s 2026 annual shareholder meeting (exact meeting date not yet set).
Following the grant, Mr. Dadoo beneficially owns 30,000 derivative securities (options) in a direct capacity; no open-market purchases or sales of common stock were disclosed. The filing indicates a routine annual director equity award rather than a discretionary transaction, and no Rule 10b5-1 trading plan box was checked.
Because the transaction is an option grant—not a purchase or sale—it does not immediately affect float or insider ownership percentages, but it does align the director’s incentives with shareholder value creation over the next decade. Investors typically view such grants as neutral-to-modestly positive signals, reinforcing board commitment without implying near-term trading intentions.
Form 4 highlights: On 06/25/2025 ARS Pharmaceuticals, Inc. (SPRY) granted Director Pratik Shah a stock option for 30,000 common shares at an exercise price of $17.26 per share. The option vests in full on the earlier of 25 June 2026 or the date of the company’s 2026 annual shareholder meeting, and expires on 24 June 2035. Following this grant, Mr. Shah beneficially owns 30,000 derivative securities; all are held directly. No non-derivative share transactions were reported.
The filing reflects a routine equity incentive award to a non-employee director and does not indicate any open-market buying or selling. As such, it provides limited insight into current insider sentiment but does add a small potential dilutive element (≈30 k shares) to SPRY’s future share count if and when the option is exercised.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider filing dated 06/27/2025
Director Michael Kelly was granted a non-qualified stock option for 30,000 common shares on 06/25/2025 at an exercise price of $17.26 per share. The option vests in full on the earlier of June 25, 2026 or the date of the company’s 2026 annual meeting of stockholders, and carries a ten-year term expiring on 06/24/2035.
The filing reports no open-market purchases or sales of common stock; all activity relates to derivative securities. Following the grant, Mr. Kelly’s beneficial ownership comprises 30,000 derivative securities held directly. No indirect holdings or other related-party transactions were disclosed.
This one-year vesting schedule is consistent with typical board compensation practices and is intended to align the director’s incentives with shareholder interests. Because the award represents routine director compensation and does not involve cash expenditures or immediate dilution, it is unlikely to have a material impact on near-term financial performance or share count.
Form 4 filing overview – ARS Pharmaceuticals, Inc. (SPRY)
On 25 June 2025, director Saqib Islam received a new grant of derivative securities in the form of stock options. The filing reports one transaction and shows no changes to any non-derivative share holdings.
- Security granted: Stock option (right to buy)
- Amount: 30,000 options
- Exercise price: $17.26 per share
- Date exercisable: Grant vests in full on the earlier of 25 June 2026 or the company’s 2026 annual meeting.
- Expiration: 24 June 2035 (10-year term)
- Ownership after transaction: 30,000 derivative securities held directly by the reporting person.
The transaction is coded "A" (acquired), indicating an option grant rather than an open-market purchase or sale. No price was paid for the option itself; the $17.26 will be payable only upon future exercise. The filing shows Mr. Islam continues to serve as a director of ARS Pharmaceuticals and submitted the form individually. No other insiders or joint filers are listed.
Investors should note that the grant aligns the director’s potential future ownership with shareholder value creation, but it does not immediately affect the company’s outstanding share count or cash position.
ARS Pharmaceuticals, Inc. (SPRY) filed a Form 4 on 06/27/2025 disclosing an equity award to director Peter A. Thompson. The transaction, dated 06/25/2025, involves the grant of 30,000 non-qualified stock options with an exercise price of $17.26 per share, corresponding to the company’s common stock.
The options vest in full on the earlier of June 25 2026 or the date of SPRY’s 2026 annual shareholder meeting, and they carry a 10-year term expiring on June 24 2035. Following the grant, Thompson’s beneficial ownership consists solely of these 30,000 derivative securities, reported as direct (D) ownership.
Per a standing agreement, all economic benefits from the award will be transferred to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which in turn will pass them to OrbiMed Private Investments VI, LP. No open-market purchase or sale of common shares was reported, and no changes were disclosed for non-derivative holdings.
This filing represents a routine director compensation grant that modestly increases SPRY’s potential share count but primarily serves to align long-term incentives with shareholder value.
Form 4 Overview: On 06/25/2025, ARS Pharmaceuticals, Inc. (ticker: SPRY) filed a Form 4 detailing an insider transaction by Director Brent L. Saunders.
Key Details:
- Security Granted: Stock Option (right to buy common stock)
- Quantity: 30,000 options
- Exercise Price: $17.26 per share
- Grant Date: 06/25/2025
- Expiration: 06/24/2035
- Vesting: 100% on the earlier of 25 June 2026 or the date of the company’s 2026 annual shareholder meeting (exact meeting date not yet set).
- Ownership Form: Direct (D)
No common shares were bought or sold in Table I; the filing solely reports an acquisition of derivative securities in Table II. Following the grant, Saunders beneficially owns 30,000 derivative securities (options) with no indirect holdings disclosed.
Implications for Investors: The option award is a routine director compensation action that aligns leadership incentives with shareholder value. It does not involve an open-market purchase or sale of equity and therefore has limited immediate impact on the company’s share float or insider sentiment.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider filing dated 06/27/2025
The filing reports a single equity incentive transaction for director Phillip M. Schneider. On 06/25/2025 Mr. Schneider received 30,000 non-qualified stock options with an exercise price of $17.26 per share, equal to the closing market price on the grant date (implied from standard practice; no discount indicated). The award vests in full on the earlier of June 25 2026 or the date of the company’s 2026 annual shareholders meeting, and will expire on 06/24/2035 if unexercised. No shares were sold or purchased in the open market, and there were no changes to Mr. Schneider’s previously held common shares.
Following the grant, Mr. Schneider beneficially owns 30,000 derivative securities (options) directly. The filing contains no additional derivative or non-derivative transactions, amendments, or 10b5-1 plan indications.
The transaction is typical annual director compensation and does not alter the company’s share count immediately; any potential dilution is deferred until exercise. Investors typically view such grants as routine governance practice that aligns board incentives with shareholder value but has minimal near-term financial impact.
ARS Pharmaceuticals (Nasdaq: SPRY) filed an 8-K disclosing the voting results of its 2025 Annual Meeting held on June 25, 2025.
- All four Class II director nominees—Richard Lowenthal, Peter Kolchinsky, Brenton Saunders and Peter Thompson—were elected to serve until the 2028 meeting.
- Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 with 77,258,380 votes for (≈99.5%).
No other proposals were considered and the disclosure contains no material changes to strategy, operations or financial outlook.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider transaction
Chief Commercial Officer Eric Karas exercised 15,000 stock options at an exercise price of $1.50 on 06/18/2025 (Code M) and simultaneously sold 15,000 common shares at $16.00 per share (Code S) under a Rule 10b5-1 trading plan adopted on 03/26/2024. Following these transactions, Karas directly holds 7,696 common shares and retains 559,588 outstanding options. No other derivative or non-derivative changes were reported.
The filing indicates routine option exercise and sale rather than an outright reduction of economic exposure, as the officer continues to hold a substantial option position. Investors may view the scheduled nature of the sale as mitigating potential negative sentiment typically associated with insider selling.
FAQ
What is the current stock price of ARS Pharms (SPRY)?
What is the market cap of ARS Pharms (SPRY)?
